1. Home
  2. Product Information
  3. Ziprasidone

Product Information


This program is the subject of a licensing agreement with Meiji Seika Pharma, Co., Ltd. For details, please see the Licensing Status link.

Class Second generation (atypical) anti-psychotic
Mechanism of Action D2 and 5-HT2A antagonist
Target Indication Schizophrenia, Bipolar Disorder
Overseas Development Status Marketed (Geodon)
Portfolio for development and marketing rights in Japan
Product Summary

Schizophrenia is a mental disorder which commonly manifests itself via hallucinations, paranoia and various other symptoms, and affects approximately one percent of the world’s population. Ziprasidone is an atypical antipsychotic drug and demonstrates antagonistic efficacy both on the dopamine D2 receptor and serotonin 5-HT2A receptor. Ziprasidone has some advantages over other currently available second generation antipsychotic drugs, including a low risk of body weight gain and blood sugar level increase. Sold by Pfizer Inc., ziprasidone is on the market in many countries, and accepted as a first-choice drug in its class according to guidelines for the treatment of mental disorders in the United States.

Licensing Status

Page Top

Corporate Information
CEO Message
Company Overview
Vision, Management Principle and Culture
Quality Policy
Corporate Governance
Business Model
Origins of Our Corporate Name and Logo
Press Release
Research & Development
Partnering in Research
What are Research Tools?
Research Tool Licensing
Product Information
Potassium-Competitive Acid Blocker
5-HT4 Partial Agonist
5-HT2B Antagonist
Motilin Receptor Agonist
Licensing Status
Shareholder and Investor Information
Vision, Management Principle and Culture
Corporate Governance
Outline of Securities Matters
IR Library
IR Calendar
IR Related News
Understanding RaQualia Pharma! RaQualia FAQ
RaQualia's History
What does RaQualia Pharma do?
How Does RaQualia Earn Revenues?
What About Dividends?
What are RaQualia's strengths?
What Does the Future Hold for RaQualia Pharma?
Contributions to Society
Corporate Contributions
Contributions to the Community
Press Release